← Back to Screener
IceCure Medical Ltd. Ordinary Shares (ICCM)
Price$0.36
Favorite Metrics
Price vs S&P 500 (26W)-67.54%
Price vs S&P 500 (4W)-52.36%
Market Capitalization$24.87M
All Metrics
Book Value / Share (Quarterly)$0.12
P/TBV (Annual)1.33x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)3.03%
Cash Flow / Share (Quarterly)$-0.20
Price vs S&P 500 (YTD)-45.30%
Gross Margin (TTM)36.28%
Net Profit Margin (TTM)-445.61%
EPS (TTM)$-0.24
10-Day Avg Trading Volume0.41M
EPS Excl Extra (TTM)$-0.24
Revenue Growth (5Y)-2.68%
EPS (Annual)$-0.24
ROI (Annual)-166.36%
Gross Margin (Annual)36.28%
Net Profit Margin (5Y Avg)-430.69%
Cash / Share (Quarterly)$0.12
Revenue Growth QoQ (YoY)46.17%
ROA (Last FY)-108.42%
Revenue Growth TTM (YoY)2.67%
EBITD / Share (TTM)$-0.23
ROE (5Y Avg)-122.46%
Operating Margin (TTM)-446.70%
Cash Flow / Share (Annual)$-0.20
P/B Ratio2.75x
P/B Ratio (Quarterly)4.63x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)4.73x
Net Interest Coverage (TTM)-69.75x
ROA (TTM)-118.89%
EPS Incl Extra (Annual)$-0.24
Current Ratio (Annual)2.61x
Quick Ratio (Quarterly)1.91x
3-Month Avg Trading Volume0.42M
52-Week Price Return-68.51%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.48
P/S Ratio (Annual)7.36x
Asset Turnover (Annual)0.24x
52-Week High$1.40
Operating Margin (5Y Avg)-436.51%
EPS Excl Extra (Annual)$-0.24
CapEx CAGR (5Y)-30.37%
26-Week Price Return-58.79%
Quick Ratio (Annual)1.96x
13-Week Price Return-47.10%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.61x
Enterprise Value$15.977
Revenue / Share Growth (5Y)-25.14%
Asset Turnover (TTM)0.27x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.93x
Pretax Margin (Annual)-445.61%
Cash / Share (Annual)$0.12
3-Month Return Std Dev103.82%
Gross Margin (5Y Avg)44.14%
Net Income / Employee (TTM)$-0
ROE (Last FY)-166.36%
Net Interest Coverage (Annual)-151.92x
EPS Basic Excl Extra (Annual)$-0.24
Receivables Turnover (TTM)12.24x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.24
Receivables Turnover (Annual)12.24x
ROI (TTM)-205.85%
P/S Ratio (TTM)7.36x
Pretax Margin (5Y Avg)-430.69%
Revenue / Share (Annual)$0.05
Tangible BV / Share (Annual)$0.56
Price vs S&P 500 (52W)-103.60%
Year-to-Date Return-41.16%
5-Day Price Return6.40%
EPS Normalized (Annual)$-0.24
ROA (5Y Avg)-81.28%
Net Profit Margin (Annual)-445.61%
Month-to-Date Return19.27%
Cash Flow / Share (TTM)$-0.41
EBITD / Share (Annual)$-0.23
Operating Margin (Annual)-446.70%
ROI (5Y Avg)-122.46%
EPS Basic Excl Extra (TTM)$-0.24
P/TBV (Quarterly)1.53x
P/B Ratio (Annual)4.63x
Inventory Turnover (TTM)0.93x
Pretax Margin (TTM)-445.61%
Book Value / Share (Annual)$0.12
Price vs S&P 500 (13W)-49.97%
Beta1.88x
Revenue / Share (TTM)$0.05
ROE (TTM)-221.04%
52-Week Low$0.28
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
ICCMIceCure Medical Ltd. Ordinary Shares | 7.36x | -2.68% | 36.28% | -446.70% | $0.36 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
Icecure Medical develops minimally invasive cryoablation systems using liquid nitrogen to treat solid tumors across multiple indications, including breast, lung, kidney, and bone cancers. The company's technology offers patients an alternative to traditional surgical intervention with reduced recovery time and lower risk. As a commercial-stage company, Icecure is focused on expanding adoption of its cryoablation platform across oncology markets.